In Q1 2026, Deep Track Capital held 58 positions worth $4.6B. They initiated 8 new positions and exited 91. Their largest holding was GH ($308.4M). Portfolio value grew +14.2% versus the prior quarter.
Frequently asked questions
What stocks did Deep Track Capital own in Q1 2026?
Deep Track Capital held 58 biotech stocks in their 13F portfolio in Q1 2026. Their top positions include GH, IMVT, TARS, PCVX, GPCR. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Deep Track Capital's portfolio worth in Q1 2026?
Deep Track Capital's tracked biotech portfolio was worth $4.6B across 58 positions, with total assets under management of approximately $5B. Portfolio values are based on 13F filings with the SEC.
What did Deep Track Capital buy in Q1 2026?
Deep Track Capital initiated 8 new positions in Q1 2026, including ALMS, DFTX, CRVS, MANE, SLDB and 3 more. They also increased 30 existing positions.
What did Deep Track Capital sell in Q1 2026?
Deep Track Capital fully exited 91 positions in Q1 2026, including AKRO, CNTX, ACAD, ETNB, UPB and 86 more. They also trimmed 12 existing positions.
Is Deep Track Capital a biotech fund?
Greenwich-based life sciences investment advisor founded by David Kroin, who previously co-founded Great Point Partners. Invests across public and private biotech, pharmaceutical, and medical device companies with over 25 years of healthcare investment expertise driving concentrated, high-conviction positioning.
Want AI analysis, insider signals, and catalyst overlays for Deep Track Capital?
View latest Deep Track Capitalportfolio →